

# PAPER PRESENTATION

## SUPPORTING DOCUMENTS

1. TITLE OF THE PAPER: Characterization, *in vitro* cytotoxic and antibacterial exploitation of green synthesized freshwater cyanobacterial silver nanoparticles

NAME OF THE AUTHOR: DR. Kuraganti Gunaswetha

Journal of Applied Pharmaceutical Science Vol. 10(09), pp 088-098, September, 2020  
Available online at <http://www.japsonline.com>  
DOI: 10.7324/JAPS.2020.10911  
ISSN 2251-3354



### Characterization, *in vitro* cytotoxic and antibacterial exploitation of green synthesized freshwater cyanobacterial silver nanoparticles

Guna Swetha Kuraganti, Sujatha Edla\*, Thrimothy Dasari, Mamatha Reddy  
Department of Microbiology, Kakatiya University, Hanamkonda, India.

#### ARTICLE INFO

Received on: 18/03/2020  
Accepted on: 17/07/2020  
Available online: 05/09/2020

#### Key words:

Freshwater cyanobacteria, silver nanoparticles, characterization, antimicrobial activity, cytotoxic activity.

#### ABSTRACT

Cyanobacteria-mediated silver nanoparticles synthesis approach has proven to be more efficient and eco-friendly in achieving biomedical applications compared to physical and chemical prototypes. In the present work, the silver nanoparticles were successfully synthesized by cell-free extract of freshwater cyanobacteria, i.e., *Chroococcus nongardii* and *Characium typicum*. The cyanobacterial silver nanoparticles (CSNPs) were characterized by UV-Vis spectroscopy, scanning electron microscopy (SEM), transmission electron microscopy (TEM), and Fourier transform infrared (FTIR) analysis and were further tested for antibacterial and cytotoxic efficiency. The synthesis of CSNPs was confirmed through visible color change and shift of peaks at 430–445 nm by the UV-Vis spectroscopy. The size of CSNPs was between 22 and 34 nm and oval-shaped which were confirmed by SEM and TEM analyses. The FTIR spectra showed a new peak at the range of 3,400–3,460  $\text{cm}^{-1}$  compared to control, confirming the reduction of silver nitrate. Furthermore, the antibacterial activity of CSNPs showed highest zone of inhibition with 6.9, 4.0, 2.0, and 3.0 mm against *Salmonella paratyphi*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Staphylococcus aureus*, respectively, whereas *in vitro* cytotoxic activity of *C. typicum* and *C. nongardii* silver nanoparticles showed remarkable  $\text{IC}_{50}$  values with 43.3 and 40.9  $\mu\text{g/ml}$  against MCF-7 breast cancer cell line and 20.8 and 55.7  $\mu\text{g/ml}$  against HepG2 cancer cell, simultaneously.

#### INTRODUCTION

Nanoscience is an emerging field of nanobiotechnology, utilizing nanobased systems for various biomedical applications. The nanoparticles generally lie in the range of  $10^{-9}$  nm with dimensions of 1–100 nm (Sharma *et al.*, 2016). Consequently, nanoparticles exhibit therapeutic properties because of their high surface volume, strong binding affinity, and their ability to easily diffuse into the cell (Sun *et al.*, 2014). Among other nanoparticles, silver nanoparticles have prudent specific conductivity and stability with unique therapeutic, antibacterial, and catalytic properties which makes them important in nanooncology and in the diagnosis and treatment of cancer through nanodevices and therapeutic agents (Husain *et al.*, 2015). The synthesis of nanoparticles through physical and chemical processes consumes extreme


energy, pollutes the environment, produces toxic chemicals that stick to the surface of particles, and which have inimical effects in medical applications (Nadagouda and Varma, 2008). Green synthesis of nanoparticles is convenient over physical and chemical methods of nanoparticle synthesis, since biologically synthesized nanoparticles are more eco-friendly and energy efficient for the synthesis of inorganic nanoparticles (Jeffryes *et al.*, 2015; Mittal *et al.*, 2013) and economically feasible compared to physical and chemical synthesis.

Green synthesis of nanoparticles is generally carried out by the living forms of bacteria, fungi, viruses, plant extracts, plant parts, algae, yeast, and cyanobacteria (Keskin *et al.*, 2016; Kharissova *et al.*, 2013; Pirtarighat *et al.*, 2019; Swaminathanalyer, 2013). Among the biological systems, cyanobacteria are preferable since they can be easily cultivated with a high growth rate and they reduce silver ions expeditiously (Roychoudhury *et al.*, 2016). Cyanobacteria are one of the prominent bio-factories that produce a wide range of bioactive compounds, i.e., secondary metabolites, like minerals, lipids, proteins, polysaccharides, carbohydrates, carotenoids, and

\*Corresponding Author  
Sujatha Edla, Department of Microbiology, Kakatiya University,  
Hanamkonda, India. E-mail: [sujathaedla\\_1973@kakatiya.ac.in](mailto:sujathaedla_1973@kakatiya.ac.in)

2. TITLE OF THE PAPER: Use of Electronic Resources by the faculty members of engineering colleges: A case study of Kakatiya Institute of Technology and Science (KITS) (Autonomous), Warangal, Telangana State

NAME OF THE AUTHOR: DR. R. Lalitha



### 3. TITLE OF THE PAPER: Synthesis and biological evaluation of aryl sulfonyl linked isoxazol-(pyridin-4-yl) pyrazolo [1,5-a] pyrimidines as cytotoxicity agents

NAME OF THE AUTHOR: Rasam Savitha

Chemical Data Collections 38 (2022) 100822



Contents lists available at ScienceDirect

Chemical Data Collections

journal homepage: [www.elsevier.com/locate/cdc](http://www.elsevier.com/locate/cdc)



Data Article

#### Synthesis and biological evaluation of aryl sulfonyl linked isoxazol-(pyridin-4-yl)pyrazolo [1,5-a]pyrimidines as cytotoxicity agents



G. Sabita, R. Savitha, K. Divya, K. Bhaskar\*

Department of Chemistry, Osmania University, Hyderabad, Telangana 500007, India

#### ARTICLE INFO

**Keywords:**  
Dinaciclib  
Pyrazolo [1,5-a]pyrimidine  
Luminesplab  
1,2-isoxazole and cytotoxicity activity

#### ABSTRACT

A new bunch of aryl sulfonyl linked isoxazol-(pyridin-4-yl)pyrazolo [1,5-a]pyrimidine compounds (11a-j) have been designed, developed and their structure were characterized by analytical techniques. Further, compounds were tested for their cytotoxicity activities towards human cancer cell lines like SiHa (Cervix cancer), A549 (Lung cancer), MCF-7 (Breast cancer) and Colo-205 (Colon cancer) using MTT assay and compared with standard drug, etoposide. Among all, compounds 11a, 11b, 11c, 11d and 11e demonstrated good cytotoxicity effects as standard drug. Specifically, two compounds (11a and 11e) displayed more potent activity.

#### Specifications table

|                         |  |
|-------------------------|--|
| Subject area            | Organic Chemistry, Biochemistry, Spectroscopy  |
| Compounds               | Aryl Sulfonyl Linked Isoxazol-(pyridin-4-yl)pyrazolo [1,5-a]pyrimidine as Cytotoxicity Agents  |
| Data category           | Spectral   |
| Data acquisition format | NMR, HRMS(ESI)   |
| Data type               | Analyzed   |
| Procedure               | Synthesis and Biological Evaluation of Aryl Sulfonyl Linked Isoxazol-(pyridin-4-yl)pyrazolo [1,5-a]pyrimidine as Cytotoxicity Agents |
| Data accessibility      | Manuscript and supplementary data enclosed with this article   |

#### 1. Rationale

Nitrogen-heterocyclic moieties are played a significant function in real life and biological progressions. The pyrazolo [1,5-a] pyrimidines are well known of fused heterocyclic building blocks represent useful chemotherapeutics and had great attention of medicinal chemist because of its biological applications. They are structural and pharmacologically similar to purine bases [1,2]. The pyrazolo [1,5-a]pyrimidine skeleton consisted heterocyclic compounds displayed a broad range of biological applications including antimicrobial [3], CNS depressant [4], tuberculostatic [5], antihypertensive [6], neuroleptic [7], analgesic [8], antitumor [9], anti-inflammatory [10] and anti-viral [11]. Among, the Dinaciclib (1, Fig. 1) is contained pyrazo-pyrimidine unit as back-bone of the

\* Corresponding author.  
E-mail address: [Kbhaskar1279@gmail.com](mailto:Kbhaskar1279@gmail.com) (K. Bhaskar).

<https://doi.org/10.1016/j.cdc.2021.100822>

Received 26 November 2021; Received in revised form 24 December 2021; Accepted 25 December 2021  
Available online 27 December 2021  
2405-8300/© 2021 Elsevier B.V. All rights reserved.